Immatics N.V. (IMTX)

10,88 +0,05 (+0,46%) Ab 10:03AM EDT. Markt geöffnet.

Immatics N.V.

Paul-Ehrlich-Strasse 15
Tübingen 72076
Germany
49 7071 5397 0
https://www.immatics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 432

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Harpreet Singh Ph.D.	CEO, MD, Member of Management Board & Executive Director	894,16k	N/A	1975
Dr. Toni Weinschenk Ph.D.	Co-Founder & Chief Innovation Officer	N/A	N/A	1974
Mr. Arnd Christ MBA	Chief Financial Officer	N/A	N/A	1966
Mr. Steffen Walter Ph.D.	Chief Operations Officer	N/A	N/A	1977
Mr. Edward A. Sturchio J.D.	General Counsel & Secretary	N/A	N/A	1976
Dr. Carsten Reinhardt M.D., Ph.D.	Chief Development Officer	N/A	N/A	1967
Mr. Cedrik M. Britten M.D.	Chief Medical Officer	N/A	N/A	1976
Mr. Jordan Silverstein	Head of Strategy	N/A	N/A	1980
Dr. Hans-Georg Rammensee Ph.D.	Co-Founder & Member of the Scientific Advisory Board	N/A	N/A	N/A
Mr. Ephraim Hofsäß M.Sc.	Vice President of SEC Reporting & Accounting	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Corporate Governance

Immatics N.V.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.